Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06422143
Title Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ROU | POL | ITA | ISR | HUN | GBR | ESP | DEU | CZE | CAN | BRA | AUT | ARG


No variant requirements are available.